ST Elevation Myocardial InfarctionNCT06535503
Clinical Characteristics and Outcomes Among STEMI Patients With Cardiogenic Shock at Abu Dhabi City
An observational study of ST Elevation Myocardial Infarction and Cardiogenic Shock, run by Abu Dhabi Health Services Company at 2 sites in United Arab Emirates.
Trial summary
A retrospective study on the clinical characteristics and treatment outcomes of patients admitted with ST-elevation Myocardial Infarction (STEMI) complicated with cardiogenic shock (CS) during admission or CS development during their hospital stay for two tertiary hospitals in Abu Dhabi, UAE, from 2020-2024. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- ST Elevation Myocardial Infarction, Cardiogenic Shock
- How many people
- 400 participants
- Where
- 2 sitesUnited Arab Emirates
- Study dates
- 1 Jul 2024to 30 May 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with STEMI complicated by cardiogenic shock on admission or after hospitalization were treated in Abu Dhabi city from January 2020 to January 2024.
Who may be able to join
- Age more than 18.
- STEMI complicated by cardiogenic shock.
- Were hospitalized or treated at SSMC or SKMC for STEMI complicated by cardiogenic shock.
- Patient admitted between January 2019 to March 2024.
Who cannot join
- Age less than 18.
- Shock patient not related to Myocardial infarction.
- NSTEMI-related cardiogenic shock.
- Patients who were not treated at SSMC or SKMC for the STEMI complicated by cardiogenic shock.
- Patient not admitted between January 2019 to March 2024.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United Arab Emirates2 sites, 2 recruiting
- Recruiting
Sheikh Khalifa Medical City (SKMC)
Abu Dhabi, Abu Dhabi Emirate, 11001
Abdulmajeed BS Alzubaidi, MD, 0502900663, aalzubaidi@seha.ae
Alina Naeem, MD, 0566089799, alnaeem@seha.ae
- Recruiting
Sheikh Shakhbout Medical City (SKMC)
Abu Dhabi, Abu Dhabi Emirate, 11001
Abdulmajeed BS Alzubaidi, MD, 0502900663, aalzubaidi@seha.ae
Babiker MB Elsiraj, MD, 0564972830, Belsiraj@seha.ae
About this study
Official title: Clinical Characteristics and Outcomes Among ST-elevation Myocardial Infarction (STEMI) Patients With Cardiogenic Shock at Abu Dhabi City
A retrospective study on the clinical characteristics and treatment outcomes of patients admitted with ST-elevation Myocardial Infarction (STEMI) complicated with cardiogenic shock (CS) during admission or CS development during their hospital stay for two tertiary hospitals in Abu Dhabi, UAE, from 2020-2024.
Read the detailed description
Cardiovascular disease (CVD) accounts for 40% of mortality in the UAE, which is higher than the global average. Long-term trends, incidence studies, and best practice guidance on Cardiogenic Shock (CS) with ST-elevation Myocardial infarction (STEMI) in the United Arab Emirates (UAE) and the Gulf Cooperation Council (GCC) are limited.
Through this retrospective study, investigators aim to identify treatment modalities and trends, hospitalization events, and patient demographics and comorbidities which lead to participant recovery or mortality in Sheikh Khalifa Medical City (SKMC) and Sheikh Shakhbout Medical City (SSMC) tertiary hospitals for patients admitted with STEMI and CS or developed CS after hospitalization with STEMI during January 2020-January 2024.[200-400 participants]. Data will be collected from eligible patients' electronic medical records (EMR).
- Keywords
- STEMI, Cardiogenic Shock, Morbidity, Mortality
- Medical subject headings
- ST Elevation Myocardial Infarction, Shock, Cardiogenic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with STEMI & Cardiogenic Shock | Patients with STEMI complicated by cardiogenic shock on admission or after hospitalization treated at SKMC \& SSMC, Abu Dhbai |
What is being measured
The primary outcome is the main question the study is designed to answer.
Analyze STEMI patient with CS disease profile
Comorbidities, demographical information, past medical history, morbidity
Measured: 5 years
Incidence of CS-complicated AMI events
The incidence of CS-complicated AMI events will show an increase over the years because of advanced diagnostic modalities and a clearer definition of CS.
Measured: 5 years
Analyze treatment outcomes in the targeted population as per the patient profile
Incidence of Mortality
Measured: 5 years
Analyze STEMI patient with CS disease profile
Incidence of Morbidity
Measured: 5 years
Analyze treatment outcomes
% of patients who were discharged
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Aug 2024
- Study start1 Jul 2024
- Primary completion1 Jan 2025
- Study completion30 May 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for ST Elevation Myocardial InfarctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Abu Dhabi Health Services Company
- Sponsor type
- Other government
- Collaborators
- Sheikh Shakhbout Medical City, Sheikh Khalifa Medical City
- Responsible party
- Principal investigator, Babiker Mohamed Babiker Elsiraj, Abu Dhabi Health Services Company
- Investigators
- Abdulmajeed BS Alzubaidi, MD, Study chair, Abu Dhabi Health Services Co. -SEHABabiker Babiker Mohamed Babiker Elsiraj MB Elsiraj, Principal investigator, Sheikh Shakhbout Medical City
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06535503
- Sponsor's protocol ID
- SEHAResearch ID 747
- Status last verified
- Feb 2025
- First submitted
- 13 May 2024
- Last updated
- 17 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The plan is to share the clinical study report with all researchers. We will share the study protocol and case report form if further collaboration is decided while expanding our study.
Publications
Al-Shamsi S, Regmi D, Govender RD. Incidence of cardiovascular disease and its associated risk factors in at-risk men and women in the United Arab Emirates: a 9-year retrospective cohort study. BMC Cardiovasc Disord. 2019 Jun 17;19(1):148. doi: 10.1186/s12872-019-1131-2.
PubMed 31208354Akbar H, Sharma S. Acute ST-Segment Elevation Myocardial Infarction (STEMI). 2024 Oct 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK532281/
PubMed 30335314De Luca L, Olivari Z, Farina A, Gonzini L, Lucci D, Di Chiara A, Casella G, Chiarella F, Boccanelli A, Di Pasquale G, De Servi S, Bovenzi FM, Gulizia MM, Savonitto S. Temporal trends in the epidemiology, management, and outcome of patients with cardiogenic shock complicating acute coronary syndromes. Eur J Heart Fail. 2015 Nov;17(11):1124-32. doi: 10.1002/ejhf.339. Epub 2015 Sep 4.
PubMed 26339723Holmes DR Jr, Bates ER, Kleiman NS, Sadowski Z, Horgan JH, Morris DC, Califf RM, Berger PB, Topol EJ. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1995 Sep;26(3):668-74. doi: 10.1016/0735-1097(95)00215-p.
PubMed 7642857Shalaby G, Niazi AK, Khaled S. Cardiogenic Shock Among Patients with Acute ST-Segment Elevation Myocardial Infarction in a Middle Eastern Country: A Single-Center Experience. J Saudi Heart Assoc. 2023 Jan 20;34(4):232-240. doi: 10.37616/2212-5043.1323. eCollection 2022.
PubMed 36816794Yusufali A, Bazargani N, Muhammed K, Gabroun A, AlMazrooei A, Agrawal A, Al-Mulla A, Hajat C, Baslaib F, Philip J, Gupta P, Bakir S, Krishnan S, Almahmeed W, Alsheikh-Ali A. Opportunistic Screening for CVD Risk Factors: The Dubai Shopping for Cardiovascular Risk Study (DISCOVERY). Glob Heart. 2015 Dec;10(4):265-72. doi: 10.1016/j.gheart.2015.04.008. Epub 2015 Aug 11.
PubMed 26271552
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Characteristics and Outcomes Among ST-elevation Myocardial Infarction (STEMI) Patients With Cardiogenic Shock at Abu Dhabi City
- ClinicalTrials.gov ID
- NCT06535503
- Acronym / sponsor ID
- SEHAResearch ID 747
- Keywords
- STEMI, Cardiogenic Shock, Morbidity, Mortality
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Abu Dhabi Health Services CompanyOther government
- Collaborators
- Sheikh Shakhbout Medical City, Sheikh Khalifa Medical City
- Study start
- 1 Jul 2024 (actual)
- Primary completion
- 1 Jan 2025 (actual)
- Study completion
- 30 May 2025 (estimated)
- First posted
- 2 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A retrospective study on the clinical characteristics and treatment outcomes of patients admitted with ST-elevation Myocardial Infarction (STEMI) complicated with cardiogenic shock (CS) during admission or CS development during their hospital stay for two tertiary hospitals in Abu Dhabi, UAE, from 2020-2024.
Detailed description
Cardiovascular disease (CVD) accounts for 40% of mortality in the UAE, which is higher than the global average. Long-term trends, incidence studies, and best practice guidance on Cardiogenic Shock (CS) with ST-elevation Myocardial infarction (STEMI) in the United Arab Emirates (UAE) and the Gulf Cooperation Council (GCC) are limited.
Through this retrospective study, investigators aim to identify treatment modalities and trends, hospitalization events, and patient demographics and comorbidities which lead to participant recovery or mortality in Sheikh Khalifa Medical City (SKMC) and Sheikh Shakhbout Medical City (SSMC) tertiary hospitals for patients admitted with STEMI and CS or developed CS after hospitalization with STEMI during January 2020-January 2024.[200-400 participants]. Data will be collected from eligible patients' electronic medical records (EMR).
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with STEMI & Cardiogenic Shock | – | –Patients with STEMI complicated by cardiogenic shock on admission or after hospitalization treated at SKMC \& SSMC, Abu Dhbai |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with STEMI complicated by cardiogenic shock on admission or after hospitalization were treated in Abu Dhabi city from January 2020 to January 2024.
Key inclusion criteria (4 listed)
- Age more than 18.
- STEMI complicated by cardiogenic shock.
- Were hospitalized or treated at SSMC or SKMC for STEMI complicated by cardiogenic shock.
- Patient admitted between January 2019 to March 2024.
Key exclusion criteria (5 listed)
- Age less than 18.
- Shock patient not related to Myocardial infarction.
- NSTEMI-related cardiogenic shock.
- Patients who were not treated at SSMC or SKMC for the STEMI complicated by cardiogenic shock.
- Patient not admitted between January 2019 to March 2024.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Analyze STEMI patient with CS disease profile
Time frame: 5 years
Comorbidities, demographical information, past medical history, morbidity
Incidence of CS-complicated AMI events
Time frame: 5 years
The incidence of CS-complicated AMI events will show an increase over the years because of advanced diagnostic modalities and a clearer definition of CS.
Analyze treatment outcomes in the targeted population as per the patient profile
Time frame: 5 years
Incidence of Mortality
Analyze STEMI patient with CS disease profile
Time frame: 5 years
Incidence of Morbidity
Analyze treatment outcomes
Time frame: 5 years
% of patients who were discharged
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2025.
- Background: PubMed 31208354Al-Shamsi S, Regmi D, Govender RD. Incidence of cardiovascular disease and its associated risk factors in at-risk men and women in the United Arab Emirates: a 9-year retrospective cohort study. BMC Cardiovasc Disord. 2019 Jun 17;19(1):148. doi: 10.1186/s12872-019-1131-2.
- Background: PubMed 30335314Akbar H, Sharma S. Acute ST-Segment Elevation Myocardial Infarction (STEMI). 2024 Oct 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK532281/
- Background: PubMed 26339723De Luca L, Olivari Z, Farina A, Gonzini L, Lucci D, Di Chiara A, Casella G, Chiarella F, Boccanelli A, Di Pasquale G, De Servi S, Bovenzi FM, Gulizia MM, Savonitto S. Temporal trends in the epidemiology, management, and outcome of patients with cardiogenic shock complicating acute coronary syndromes. Eur J Heart Fail. 2015 Nov;17(11):1124-32. doi: 10.1002/ejhf.339. Epub 2015 Sep 4.
- Background: PubMed 7642857Holmes DR Jr, Bates ER, Kleiman NS, Sadowski Z, Horgan JH, Morris DC, Califf RM, Berger PB, Topol EJ. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1995 Sep;26(3):668-74. doi: 10.1016/0735-1097(95)00215-p.
- Background: PubMed 36816794Shalaby G, Niazi AK, Khaled S. Cardiogenic Shock Among Patients with Acute ST-Segment Elevation Myocardial Infarction in a Middle Eastern Country: A Single-Center Experience. J Saudi Heart Assoc. 2023 Jan 20;34(4):232-240. doi: 10.37616/2212-5043.1323. eCollection 2022.
- Background: PubMed 26271552Yusufali A, Bazargani N, Muhammed K, Gabroun A, AlMazrooei A, Agrawal A, Al-Mulla A, Hajat C, Baslaib F, Philip J, Gupta P, Bakir S, Krishnan S, Almahmeed W, Alsheikh-Ali A. Opportunistic Screening for CVD Risk Factors: The Dubai Shopping for Cardiovascular Risk Study (DISCOVERY). Glob Heart. 2015 Dec;10(4):265-72. doi: 10.1016/j.gheart.2015.04.008. Epub 2015 Aug 11.
- Kosaraju, A., Pendela, V. S., \& Hai, O. (2023, April 7). Cardiogenic shock. StatPearls \[Internet\]. https://www.ncbi.nlm.nih.gov/books/NBK482255/Link provided by the sponsor.
- High prevalence of cardiometabolic risk factors amongst young adults in the United Arab Emirates: The UAE Healthy Future Study.Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. The plan is to share the clinical study report with all researchers. We will share the study protocol and case report form if further collaboration is decided while expanding our study.
Related trials for ST Elevation Myocardial Infarction
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
RecruitingPhase 2
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
Myocardial Infarction, Reperfusion Injury
Not yet recruitingObservational study
Incremental Prognostic Utility of CBC-derived Inflammatory Indices After Incomplete Coronary Revascularization: Association With 12-months Cardiovascular Outcomes
STEMI, High Risk NSTEMI
RecruitingObservational study
SuperSaturated Oxygen Comprehensive Observational Registry
STEMI - ST Elevation Myocardial Infarction, AMI
RecruitingPhase 4
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
ST Elevation Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Abdulmajeed BS Alzubaidi, MD study chair
Abu Dhabi Health Services Co. -SEHA
Babiker Babiker Mohamed Babiker Elsiraj MB Elsiraj principal investigator
Sheikh Shakhbout Medical City
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of ST Elevation Myocardial Infarction and Cardiogenic Shock, run by Abu Dhabi Health Services Company at 2 sites in United Arab Emirates.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Arab Emirates. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alina Naeem, MBBS (0097124102534, alnaeem@seha.ae), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Analyze STEMI patient with CS disease profile (time frame: 5 years). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06535503, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2025; AzTrials last refreshed its copy on 8 Nov 2026.